Eli Lilly and Company (LLY)
Insights Into Lilly (LLY) Q2: Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Lilly (LLY) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Should You Buy, Sell or Hold Lilly Stock Ahead of Q2 Earnings?
LLY eyes Q2 growth on Mounjaro and Zepbound momentum, but pricing pressure and rising competition test its edge.
Trim Your AI Stocks And Buy Eli Lilly
AI and semiconductor stocks are too expensive right now. Don't buy them now, trim your high-tech positions, and buy healthcare stocks like Eli Lilly and Company. LLY is a hyper-growth-at-a-reasonable-price play. A 30% 12-month return is reasonable to anticipate. It is not too early to buy healthcare stocks; it will just require patience. I'd rather leave the party first and miss the traffic than move with the crowd.
Eli Lilly: The Worst May Be Already Over (Earnings Preview)
Eli Lilly (LLY) is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Analysts expect continued volume-driven revenue and margin expansion, with consensus seeing EPS and sales growth well above industry averages through 2026. LLY's Q1 saw 45% revenue growth but a minor EPS miss due to IPR&D charges; management reaffirmed full-year guidance, and volume growth is expected to offset price erosion.
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the older drug Trulicity.
Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity
Eli Lilly said its blockbuster diabetes drug Mounjaro showed similar heart health benefits as the company's older diabetes treatment, Trulicity, in a late-stage trial directly comparing the two medicines. The drugmaker said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2 diabetes.
Eli Lilly (LLY) Declines More Than Market: Some Information for Investors
Eli Lilly (LLY) reached $762.95 at the closing of the latest trading day, reflecting a -5.59% change compared to its last close.
Lilly set for strong quarter after Novo profit warning
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook and updates on an experimental obesity drug to gauge the U.S. drugmaker's longer-term health.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
How Will Eli Lilly's Oncology Drugs Perform in Q2 Earnings?
LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
The excitement around artificial intelligence (AI) has led to most attention—and capital–being concentrated in one corner while forgetting others, creating a gap and massive opportunity for rotation into some of these forgotten names that still carry greatly attractive fundamental profiles.
